Cargando…
A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers
Metabolic reprogramming is a hallmark of cancers, but pan-cancer level roles of lipid metabolism in cancer development are remains poorly understood. We investigated the possible roles of lipid metabolic genes (LMGs) in 14 cancer types. The results indicate that: (1) there is strong evidence for inc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447541/ https://www.ncbi.nlm.nih.gov/pubmed/37612422 http://dx.doi.org/10.1038/s41598-023-41107-3 |
_version_ | 1785094574766555136 |
---|---|
author | Liu, Guoqing Yang, Yan Kang, Xuejia Xu, Hao Ai, Jing Cao, Min Liu, Guojun |
author_facet | Liu, Guoqing Yang, Yan Kang, Xuejia Xu, Hao Ai, Jing Cao, Min Liu, Guojun |
author_sort | Liu, Guoqing |
collection | PubMed |
description | Metabolic reprogramming is a hallmark of cancers, but pan-cancer level roles of lipid metabolism in cancer development are remains poorly understood. We investigated the possible roles of lipid metabolic genes (LMGs) in 14 cancer types. The results indicate that: (1) there is strong evidence for increased lipid metabolism in THCA and KICH. (2) Although the overall levels of lipid metabolic processes are down-regulated in some cancer types, fatty acid synthase activity and fatty acid elongation are moderately up-regulated in more than half of the cancer types. Cholesterol synthesis is up-regulated in five cancers including KICH, BLCA, COAD, BRCA, UCEC, and THCA. (3) The catabolism of cholesterols, triglycerides and fatty acids is repressed in most cancers, but a specific form of lipid degradation, lipophagy, is activated in THCA and KICH. (4) Lipid storage is enhanced in in kidney cancers and thyroid cancer. (5) Similarly to primary tumors, metastatic tumors tend to up-regulate biosynthetic processes of diverse lipids, but down-regulate lipid catabolic processes, except lipophagy. (6) The frequently mutated lipid metabolic genes are not key LMGs. (7) We established a LMG-based model for predicting cancer prognosis. Our results are helpful in expanding our understanding of the role of lipid metabolism in cancer. |
format | Online Article Text |
id | pubmed-10447541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104475412023-08-25 A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers Liu, Guoqing Yang, Yan Kang, Xuejia Xu, Hao Ai, Jing Cao, Min Liu, Guojun Sci Rep Article Metabolic reprogramming is a hallmark of cancers, but pan-cancer level roles of lipid metabolism in cancer development are remains poorly understood. We investigated the possible roles of lipid metabolic genes (LMGs) in 14 cancer types. The results indicate that: (1) there is strong evidence for increased lipid metabolism in THCA and KICH. (2) Although the overall levels of lipid metabolic processes are down-regulated in some cancer types, fatty acid synthase activity and fatty acid elongation are moderately up-regulated in more than half of the cancer types. Cholesterol synthesis is up-regulated in five cancers including KICH, BLCA, COAD, BRCA, UCEC, and THCA. (3) The catabolism of cholesterols, triglycerides and fatty acids is repressed in most cancers, but a specific form of lipid degradation, lipophagy, is activated in THCA and KICH. (4) Lipid storage is enhanced in in kidney cancers and thyroid cancer. (5) Similarly to primary tumors, metastatic tumors tend to up-regulate biosynthetic processes of diverse lipids, but down-regulate lipid catabolic processes, except lipophagy. (6) The frequently mutated lipid metabolic genes are not key LMGs. (7) We established a LMG-based model for predicting cancer prognosis. Our results are helpful in expanding our understanding of the role of lipid metabolism in cancer. Nature Publishing Group UK 2023-08-23 /pmc/articles/PMC10447541/ /pubmed/37612422 http://dx.doi.org/10.1038/s41598-023-41107-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Liu, Guoqing Yang, Yan Kang, Xuejia Xu, Hao Ai, Jing Cao, Min Liu, Guojun A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title | A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title_full | A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title_fullStr | A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title_full_unstemmed | A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title_short | A pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
title_sort | pan-cancer analysis of lipid metabolic alterations in primary and metastatic cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447541/ https://www.ncbi.nlm.nih.gov/pubmed/37612422 http://dx.doi.org/10.1038/s41598-023-41107-3 |
work_keys_str_mv | AT liuguoqing apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT yangyan apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT kangxuejia apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT xuhao apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT aijing apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT caomin apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT liuguojun apancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT liuguoqing pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT yangyan pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT kangxuejia pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT xuhao pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT aijing pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT caomin pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers AT liuguojun pancanceranalysisoflipidmetabolicalterationsinprimaryandmetastaticcancers |